Among three patients with rheumatoid arthritis, we demonstrated a trend towards increased CYP3A4 activity after 3 weeks of anti-IL-6R therapy, which normalized to baseline after 12 weeks of treatment. This evidence concerns the gene CYP3A4 and rheumatoid arthritis.